The conference emphasized that to do a good job in drug supervision next year, we must adhere to stability, improve quality and efficiency, focus on creating an open, transparent, and predictable drug supervision environment, stabilize the overall drug safety situation, promote innovation in pharmaceutical research and development, improve the quality and efficiency, and strive to contribute more drug supervision to the overall economic development of the country. First, it is necessary to further raise the level of drug safety and security, continuously improve the drug safety responsibility system, improve the normalized drug safety risk consultation mechanism, and resolve risks in the bud. Second, it is necessary to further support the high-quality development of the pharmaceutical industry, improve the quality and efficiency of review and approval, implement “early intervention, one enterprise, one policy, full guidance, research and review linkage” for key varieties, and support the development of innovative drugs and medical devices. Third, it is necessary to further promote the collaborative development and management of the “Three Medicines”, carry out consistent evaluations of the quality and efficacy of generic drugs in strict accordance with internationally recognized standards, strengthen quality supervision of selected products collected, and support the inheritance, innovation and development of traditional Chinese medicine. Fourth, it is necessary to further strengthen the supervisory system and capacity building, improve the regulatory standards system, vigorously develop smart supervision and regulatory science, and raise the level of modernization of drug supervision. The meeting called for effective drug supervision at the end of the year and beginning of the New Year, strengthening the supervision of key drugs in response to the frequent incidence of respiratory diseases in winter, and ensuring a stable drug safety situation during the holidays. It is necessary to carry out all tasks vigorously and in an orderly manner, scientifically plan key tasks for next year, ensure the successful completion of the “14th Five-Year Plan” work, and achieve a good start to the “15th Five-Year Plan”.

The conference emphasized that to do a good job in drug supervision next year, we must adhere to stability, improve quality and efficiency, focus on creating an open, transparent, and predictable drug supervision environment, stabilize the overall drug safety situation, promote innovation in pharmaceutical research and development, improve the quality and efficiency, and strive to contribute more drug supervision to the overall economic development of the country. First, it is necessary to further raise the level of drug safety and security, continuously improve the drug safety responsibility system, improve the normalized drug safety risk consultation mechanism, and resolve risks in the bud. Second, it is necessary to further support the high-quality development of the pharmaceutical industry, improve the quality and efficiency of review and approval, implement “early intervention, one enterprise, one policy, full guidance, research and review linkage” for key varieties, and support the development of innovative drugs and medical devices. Third, it is necessary to further promote the collaborative development and management of the “Three Medicines”, carry out consistent evaluations of the quality and efficacy of generic drugs in strict accordance with internationally recognized standards, strengthen quality supervision of selected products collected, and support the inheritance, innovation and development of traditional Chinese medicine. Fourth, it is necessary to further strengthen the supervisory system and capacity building, improve the regulatory standards system, vigorously develop smart supervision and regulatory science, and raise the level of modernization of drug supervision. The meeting called for effective drug supervision at the end of the year and beginning of the New Year, strengthening the supervision of key drugs in response to the frequent incidence of respiratory diseases in winter, and ensuring a stable drug safety situation during the holidays. It is necessary to carry out all tasks vigorously and in an orderly manner, scientifically plan key tasks for next year, ensure the successful completion of the “14th Five-Year Plan” work, and achieve a good start to the “15th Five-Year Plan”.